Engineering Lentiviruses for Gene Delivery to Antigen-specific T cells
The technology to isolate, expand, and engineer T cells has revolutionized cancer treatment. However, ex vivo T cell manipulations currently rely on lentiviral vectors with broad tropism for all activated T cells. In this project, we leverage a novel virus pseudotyping strategy to selectively modify antigen-specific T cell phenotypes in polyclonal populations. We hypothesize that this enhanced specificity will enable in vivo modification of anti-tumor T cells, providing additional functionality while avoiding systemic toxicities.